Table 1. Summary of clinical profile of patients with MOG antibody disease.
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | Total cohort |
|---|---|---|---|---|---|---|---|
| Abbreviations: ANA, antinuclear antibody; ARR, absolute risk reduction; b, bilateral; BS, brainstem; CoN, conus medullaris; CSF, cerebrospinal fluid; EDSS, expanded disability status scale; ESR, erythrocyte sedimentation rate; LETM, longitudinally extensive transverse myelitis; Lt, left; M, motor; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; N/A, not available; Neg, negative; OCB, oligoclonal bands; ON, optic neuritis; P100, prolonged P100 latency; Pos, positive; PV, periventricular; rt, right; RTX, rituximab; S, sensory; SC, subcortex; SS-B-anti, Sjögren's syndrome type-B antibody; TM, transverse myelitis; UR, urologic; V, visual; VEP, visual evoked potential. a mean value. | |||||||
| Age | 29 | 35 | 39 | 25 | 57 | 36 | 36.8 a |
| Gender | F | M | F | M | M | F | 1:1 (M:F) |
| Onset phenotype | TM | ON (bl) | ON (lt) | ON (rt) | ON (rt) | TM | – |
| Symptom at onset | UR | V | V | V | V | M,S,UR | – |
| Pyramidal signs | Yes | Yes | No | No | Yes | Yes | 66.70% |
| EDSS at onset | 4 | 4 | 1 | 3 | 3 | 6 | 3.5 a |
| No. of attacks | 1 | 3 | 2 | 4 | 1 | 1 | 2 a |
| Relapse phenotype | Nil | ON (b) | ON (lt) | ON (rt) | Nil | Nil | – |
| ARR (before treatment) | 0 | 0.32 | 1.5 | 2.77 | 0 | 0 | 0.77 a |
| ESR (mm/1st h) | 9 | 2 | 20 | 2 | 7 | 18 | 9.7 a |
| CSF cells (cells/mm 3 ) | 71 | Nil | Nil | Nil | 17.8 a | ||
| CSF protein (mg/dL) | 17 | N/A | 86 | 11 | N/A | 36 | 37.5 a |
| CSF OCB | Pos | Neg | Neg | Neg | 25% | ||
| Other autoimmunity | Nil | Nil | ANA anti-SSB | Nil | Nil | Nil | 16.70% |
| MRI lesions | LETM, CoN | ON | SC | PV | PV | SC,BS, LETM, CoN | – |
| VEP in asymptomatic eye | Nil | Absent B/L | Normal | P100 | P100 | N/A | – |
| Immunotherapy | RTX | RTX | RTX | RTX | RTX | RTX | – |
| Relapse after therapy | Nil | Nil | Nil | Nil | Nil | Nil | – |
| Follow-up duration (mo) | 8 | 7 | 6 | 3 | 5 | 5 | 5.7 a |
| Disease duration (mo) | 8 | 82 | 14 | 16 | 59 | 5 | 30.7 a |
| Prednisolone dose at follow-up (mg/d) | 10 | 10 | 0 | 0 | 0 | 0 | – |
| EDSS at follow-up | 2 | 3 | 1 | 1 | 3 | 2 | 2 a |